A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.

Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL
Clin Cancer Res. 2017 23 (1): 26-34

PMID: 27126994 · PMCID: PMC5085926 · DOI:10.1158/1078-0432.CCR-16-0134

MeSH Terms (26)

Adult Aged Antineoplastic Combined Chemotherapy Protocols Aromatase Inhibitors Biomarkers, Tumor Breast Neoplasms Cell Line, Tumor DNA Mutational Analysis Female Humans In Situ Hybridization, Fluorescence Letrozole Maximum Tolerated Dose Middle Aged Mutation Neoplasm Metastasis Neoplasm Staging Nitriles Phosphatidylinositol 3-Kinases Phosphoinositide-3 Kinase Inhibitors Receptor, ErbB-2 Receptor, Fibroblast Growth Factor, Type 1 Receptors, Estrogen Thiazoles Treatment Outcome Triazoles

Connections (1)

This publication is referenced by other Labnodes entities: